NCT00366548View on ClinicalTrials.gov

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

PHASE3CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Vaccines, Pneumococcal

Interventions

BIOLOGICAL

13 valent pneumococcal conjugate vaccine with Polysorbate 80

BIOLOGICAL

13 valent pneumococcal conjugate vaccine without Polysorbate 80

Trial Locations (14)

85-168

Bydgoszcz

39-200

Dębica

30-663

Krakow

31-202

Krakow

31-422

Krakow

91-347

Lodz

21-100

Lubartów

20-044

Lublin

55-120

Oborniki Śląskie

60-535

Poznan

61-709

Poznan

41-103

Siemianowice Śląskie

87-100

Torun

55-100

Trzebnica

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00366548 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants | Biotech Hunter | Biotech Hunter